DESIGN, DEVELOPMENT AND EVALUATION OF MOUTH DISSOLVING TABLETS OF TOFACITINIB CITRATE

MEGHANA RAYKAR; MALARKODI VELRAJ

doi:10.22159/ijap.2022v14i1.42810

Authors

MEGHANA RAYKAR Department of Pharmaceutical Sciences, School of Pharmaceutical Sciences, Vels Institute of Science, Technology and Advanced Studies, Chennai, Tamil Nadu, India, Chennai, Tamilnadu, India
MALARKODI VELRAJ Department of Pharmaceutical Sciences, School of Pharmaceutical Sciences, Vels Institute of Science, Technology and Advanced Studies, Chennai, Tamil Nadu, India, Chennai, Tamilnadu, India

DOI:

https://doi.org/10.22159/ijap.2022v14i1.42810

Keywords:

Mouth dissolving tablets (MDTs), Tofacitinib citrate, Sodium starch glycolate (SSG), Ludiflash, Factorial design, Bioavailability and bioequivalence (BABE)

Abstract

Objective: This study aims to Formulate Mouth Dissolving Tablets (MDTs) of Tofacitinib Citrate with the increase in bioavailability and patient compliance.

Methods: Mouth Dissolving Tablets (MDTs) of Tofacitinib Citrate were developed by full factorial design at 3²levelsand prepared by direct compression method using super integrants like sodium starch glycolate, Ludiflash. The tablets were compressed into compacts on a 10 station tablet machine. The bulk drug was characterised by determining, MP, Solubility, pH and FTIR spectra.

Results: The weight variation, hardness and diameter, thickness, friability, drug content, wetting time, in vitro disintegration time and in vitro dissolution studies, and stability study, tablet thickness, weight variation and drug content post compression parameters remained consistent and reproducible. All the formulations showed, almost 100 percent of drug release within 75 min. Formulations F1, F2 and F3 were prepared with 5 mg of SSG and 20 mg, 30 mg, and 40 mg Ludiflash which shows % release of drug in the order of F1<F2<F3. Formulations F4, F5 and F6 were prepared with 10 mg of SSG and 20 mg, 30 mg, and 40 mg Ludiflash which shows % release of drug in the order of F4<F5<F6. Formulations F7, F8 and F9 were prepared with 15 mg of SSG and 20 mg, 30 mg, and 40 mg Ludiflash which shows % release of drug in the order of F7<F8<F9.

Conclusion: It is concluded that the amount of superdisintegrants decreases disintegration time of tablets, decreases wetting time, increases the cumulative % drug release causes better absorption.

Downloads

Download data is not yet available.

References

Shyamala B, Narmada GY. Rapid dissolving tablets: A novel dosage form. Indian Pharm. 2002;13(8):9-12.

RM Thorat , VM Jadhav, VJ Kadam, SS Kamble, KP Salaskar. Development of HPTLC method for estimation of wedelolactone, quercetin and jatamansone in polyherbal formulation. Int J PharmTech Res Coden (USA) 2009;1(4):1079-91.

Avani F. Amin emerging trends in the development of orally disintegrating tablet technology pharmainfo; 2006.

Reddy PS, Bose PSC, Saritha D, Sruthi V. Formulation and evaluation of colon targeted matrix tablet using natural tree gums. Int J Pharm Pharm Sci. 2018;10(9):92-7. doi: 10.22159/ijpps.2018v10i9.27255.

Meghawati R, Borse SL, Junagade MS, Jadha AG. Formulation and evaluation of mouth dissolving tablet of amlodipine besylate. Int J Appl Pharm. 2019;11(4):132-9.

Fleischmann R, Kremer J, Cush J, Schulze Koops H, Connell CA, Bradley JD, Gruben D, Wallenstein GV, Zwillich SH, Kanik KS, ORAL Solo Investigators. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012;367(6):495-507. doi: 10.1056/NEJMoa1109071, PMID 22873530.

Guttman Yassky E, Silverberg JI, Nemoto O, Forman SB, Wilke A, Prescilla R, et al. Baricitinib in adult patients with moderate-to-severe atopic dermatitis: a phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study. J Am Acad Dermatol. 2019;80(4):913-21.e9. doi: 10.1016/j.jaad.2018.01.018, PMID 29410014.

https://www.rxlist.com/xeljanz-drug.html. [Last accessed on 10 Sep 2021]

Mukherjee A, Hazra A, Smith MK, Martin SW, Mould DR, Su C, Niezychowski W. Exposure-response characterization of tofacitinib efficacy in moderate to severe ulcerative colitis: results from a dose-ranging phase 2 trial. Br J Clin Pharmacol. 2018 Jul;84(6):1136-45. doi: 10.1111/bcp.13523, PMID 29377257.

Askari A, Nouri AK, Morrissey H, Ball PA. Janus kinase enzyme (JAK) inhibitors and Rheumatoid Arthritis: a review of the literature. Int J Curr Pharm Sci. 2019;11(6):11-4. doi: 10.22159/ijcpr.2019v11i6.36343.

Papp KA, Krueger JG, Feldman SR, Langley RG, Thaci D, Torii H, Tyring S, Wolk R, Gardner A, Mebus C, Tan H, Luo Y, Gupta P, Mallbris L, Tatulych S. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study. J Am Acad Dermatol. 2016;74(5):841-50. doi: 10.1016/j.jaad.2016.01.013. PMID 26899199.

National Center for Biotechnology Information. Pub chem compound summary for CID 9926791. Available from: https://pubchem.tofacitinib.ncbi.nlm.nih.gov/compound/tofacitinib. [Last accessed on 31 Aug 2021]

Lai F, Pini E, Angioni G, Manca ML, Perricci J, Sinico C, Fadda AM. Nanocrystals as tool to improve piroxicam dissolution rate in novel orally disintegrating tablets. Eur J Pharm Biopharm. 2011;79(3):552-8. doi: 10.1016/j.ejpb.2011.07.005, PMID 21820052.

https://aksci.com/item_detail.php? cat=x7518 [Last accessed on 17 Nov 2021].

https://go.drug bankdrugbank.com/drugs/DB08895 [Last accessed on 17 Nov 2021].

www.pharma.basf.com. [Last accessed on 17 Nov 2021]

Aksu B, Yegen G, Purisa S, Cevher E, Ozsoy Y. Optimisation of ondansetron orally disintegrating tablets using artificial neural networks. Trop J Pharm Res. 2014;13(9):1374-83. doi: 10.4314/tjpr.v13i9.1.

Pharmacotherapy Group, Faculty of Pharmacy, University of Benin. Benin City, 300001 Nigeria.

Devrajan PV, Gore SP. Melt-in-mouth tablets: innovative oral drug delivery system. Express Pharm Pulse. 2000;7:16-6.

Keny RV, Desouza C, Lourenco CF. Formulation and evaluation of rizatriptan benzoate mouth disintegrating tablets. Indian J Pharm Sci. 2010;72(1):79-85. doi: 10.4103/0250-474X.62253, PMID 20582194.

Thakariya NV, Ezhaya SB. Development and validation of UV spectrophotometric method for the estimation of tofacitinib citrate. Pharm Sci Monit. Apr–Jun 2017;8(2):401-8.

Flanagan ME, Li ZJ. Preparation of novel crystalline compound useful as inhibitors of protein kinases PCT Int. WO 2003048162 A120030612; 2003.

Flanagan ME, Blumenkopf TA, Brissette WH, Brown MF, Casavant JM, Shang Poa C, Doty JL, Elliott EA, Fisher MB, Hines M, Kent C, Kudlacz EM, Lillie BM, Magnuson KS, McCurdy SP, Munchhof MJ, Perry BD, Sawyer PS, Strelevitz TJ, Subramanyam C, Sun J, Whipple DA, Changelian PS. Discovery of CP-690, 550: A potent and selective janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection. J Med Chem. 2010;53(24):8468-84. doi: 10.1021/jm1004286, PMID 21105711.

Dnyaneshwar HR, Wale KK, Sayyed SF, Chaudhari SR. Orodispersible film dosage form: a review. World J Pharm Res. 2014;3(5):1093-111.

Srivastava SK, Verma R, Chandra V, Srivastava SP. Orally disintegrating tablets a dosage form that extends the market exclusivity and patent protection. World J Pharm Pharm Sci. 2014;3(7):526-46.

Rao MR, Sonavane V, Kulkarni S, Magar M, Zope A, Karanjkar P. Design of transdermal patch of ketoprofen by full factorial design for treatment of rheumatoid arthritis. J Drug Delivery Ther. 2019 Mar 15;9(2):197-205. doi: 10.22270/jddt.v9i2.2549.

Bala R, Khanna S, Pawar P. Polymers in fast disintegrating tablets: a review. Asian J Pharm Clin Res. 2012;5(2):8-14.

Deshpande KB, Ganesh NS. Orodispersible tablets: an overview of formulation and technology. Int J Pharm Biol Sci. 2011;2(1):726.

Panchal DM, Tiwari A, Srivastava P. A review on orodispersible tablets: a novel formulation for oral drug delivery system and its future prospective. Indo Am J Pharm Res. 2013;3(5):4149.

Bhosale NR, Kolte NS. Formulation development and evaluation of orally disintegrating tablet of chlorpheneramine maleate by sublimation technique. Int J Pharm Pharm Sci. 2019;11(9):28-36. doi: 10.22159/ijpps.2019v11i9.34387.

Gupta A, Mishra AK, Gupta V, Bansal P, Singh R, Singh AK. Recent trends of fast dissolving tablet: an overview of formulation technology. Int J Pharm Bio Arch. 2010;1(1):1-10.

Abdul Rahoem T, Singh R, Hiremath A, Shashant Nayak NS, Kamath KS. Formulation and comparative evaluation of ondansetron hydrochloride mouth dissolving tablets in India. Int J Pharm Pharm Sci. 2019;11(4):57-64.

Madan J, Sharma AK, Singh R. Fast dissolving tablets of Aloe vera gel. Trop J Pharm Res. 2009;8(1):63-70. doi: 10.4314/tjpr.v8i1.14713.

Kaushik D, Dureja H, Saini TR. Formulation and evaluation of olanzapine mouth dissolving tablets by effervescent formulation approach. J Adv Pharm Technol Res. 2004;41(4):147-92.

Gaur K, Tyagi LK, Kori ML, Nema RK. Formulation and characterization of fast disintegrating tablet of aceclofenac by using sublimation method. Int J Pharm Sci Drug Res. 2011;3(1):19-22.

Schiermeier S, Schmidt PC. Fast dispersible ibuprofen tablets. Eur J Pharm Sci. 2002;15(3):295-305. doi: 10.1016/s0928-0987(02)00011-8. PMID 11923062.

Malke S, Shidhaye S, Kadam V. Novel melt granulation using sugars for metoclopramide hydrochloride orally disintegrating tablet. Asian J Pharm Clin Res. 2009;2(1):8-72.

Furtado S, Deveswaran R, Bharath S, Basavaraj BV, Abraham S, Madhavan V. Development and characterization of orodispersible tablets of famotidine containing a subliming agent. Trop J Pharm Res. 2008;7(4):1185-9. doi: 10.4314/tjpr.v7i4.14705.

Jain CP, Naruka PS. Formulation and evaluation of fast dissolving tablets of valsartan. Int J Pharm Pharm Sci. 2009;1(1):219-26.

Nagendrakumar D, Raju SA, Shirsand SB, Para MS. Design of fast dissolving granisetron HCL tablets using novel co-processed superdisintegrants. Int J Pharm Sci Rev Res. 2010;1(1):58-62.

Shirwalkar AA, Jacob S, Joseph A, Srinivasan KK. Novel co-processed excipients of mannitol and microcrystalline cellulose for preparing fast dissolving tablet of glipizide. Ind J Pharm Sci. 2010:633-9.

Radke RS, Jadhav JK, Chajeed MR. Formulation and evaluation of orodispersible tablets of baclofen. Int J Chem Tech Res. 2009;1(3):517-21.